St. Jude Researchers Identified Neuroblastoma Gene Marker

A new genetic signature helps scientists distinguish malignant cells linked to treatment resistance.

Updated on Oct. 14, 2026 in Cancer

St. Jude Researchers Identified Neuroblastoma Gene Marker

Live Poll

Should medical research institutions prioritize sharing new study models to help other scientists develop treatments?

Researchers at St. Jude Children's Research Hospital have identified a specific gene signature that distinguishes malignant mesenchymal cells from healthy cells in neuroblastoma. This discovery, aimed at improving our understanding of treatment-resistant tumors, provides new tools for future research.

Why it matters

Identifying malignant mesenchymal cells has historically been difficult because they are easily mistaken for healthy cells within the tumor environment. This distinction is critical because these malignant cells are associated with treatment resistance and poor clinical outcomes.

In a study published in Cancer Cell, researchers analyzed 54 neuroblastoma tumors from 50 patients using single-cell RNA sequencing and spatial omics. The research identifies a unique gene signature for malignant mesenchymal cells, though the functional impact on patient care is still emerging.

The players

St. Jude Children's Research Hospital

A pediatric treatment and research facility focused on catastrophic childhood diseases, particularly childhood cancer.

St. Jude Childhood Solid Tumor Network

An institutional research network providing infrastructure and tumor models for pediatric oncology studies.

The details

Malignant mesenchymal and adrenergic cells in neuroblastoma possess distinct shapes and internal spatial organizations. The research team validated these findings through spatial transcriptomics, proteomics, electron microscopy, and chromatin profiling. They also developed new in vitro models and cell lines, supported by the St. Jude Childhood Solid Tumor Network, to help scientists evaluate new treatment strategies.

The study was published in the journal Cancer Cell in October 2026.

Health Landscape

This work represents an evolution in neuroblastoma research, moving beyond broad classifications to high-resolution cellular profiling. It builds upon the efforts of the St. Jude Childhood Solid Tumor Network to provide the scientific community with better tools for studying high-risk cancer.

While this laboratory discovery does not change current treatment protocols, it marks a significant step toward developing more targeted strategies for high-risk neuroblastoma. Parents and patients managing this condition should continue to discuss the latest clinical trial options and research developments with their pediatric oncologist.

The takeaway

This discovery provides researchers with a more precise way to isolate and study the malignant cells responsible for treatment resistance in neuroblastoma. For those navigating care, it underscores the value of seeking treatment at centers that actively contribute to the latest pediatric oncology research.